nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—Gangrene—Hydroxyurea—head and neck cancer	0.0826	0.168	CcSEcCtD
Ergotamine—HTR1F—trigeminal nerve—head and neck cancer	0.08	0.259	CbGeAlD
Ergotamine—Distress—Hydroxyurea—head and neck cancer	0.065	0.132	CcSEcCtD
Ergotamine—Ischaemia—Vinblastine—head and neck cancer	0.0542	0.11	CcSEcCtD
Ergotamine—Emotional distress—Hydroxyurea—head and neck cancer	0.0424	0.0864	CcSEcCtD
Ergotamine—HTR1B—trigeminal nerve—head and neck cancer	0.0328	0.106	CbGeAlD
Ergotamine—HTR1D—trigeminal nerve—head and neck cancer	0.0317	0.103	CbGeAlD
Ergotamine—Emotional distress—Fluorouracil—head and neck cancer	0.0305	0.0622	CcSEcCtD
Ergotamine—Numbness—Vinblastine—head and neck cancer	0.0238	0.0486	CcSEcCtD
Ergotamine—HTR1B—cranial nerve—head and neck cancer	0.0234	0.0755	CbGeAlD
Ergotamine—Sensory loss—Vinblastine—head and neck cancer	0.0228	0.0465	CcSEcCtD
Ergotamine—HTR1D—cranial nerve—head and neck cancer	0.0226	0.0731	CbGeAlD
Ergotamine—HTR2A—trigeminal nerve—head and neck cancer	0.0158	0.051	CbGeAlD
Ergotamine—Numbness—Fluorouracil—head and neck cancer	0.0157	0.0319	CcSEcCtD
Ergotamine—Sensory loss—Fluorouracil—head and neck cancer	0.015	0.0305	CcSEcCtD
Ergotamine—HTR2A—cranial nerve—head and neck cancer	0.0112	0.0363	CbGeAlD
Ergotamine—Hypoaesthesia—Vinblastine—head and neck cancer	0.00988	0.0201	CcSEcCtD
Ergotamine—Vertigo—Vinblastine—head and neck cancer	0.00776	0.0158	CcSEcCtD
Ergotamine—Hypertension—Vinblastine—head and neck cancer	0.00746	0.0152	CcSEcCtD
Ergotamine—HTR1F—head—head and neck cancer	0.00693	0.0224	CbGeAlD
Ergotamine—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00648	0.0132	CcSEcCtD
Ergotamine—Paraesthesia—Vinblastine—head and neck cancer	0.00633	0.0129	CcSEcCtD
Ergotamine—Pain—Vinblastine—head and neck cancer	0.00603	0.0123	CcSEcCtD
Ergotamine—HTR1E—head—head and neck cancer	0.00601	0.0194	CbGeAlD
Ergotamine—ADRA1D—epithelium—head and neck cancer	0.00593	0.0192	CbGeAlD
Ergotamine—Pain—Hydroxyurea—head and neck cancer	0.0055	0.0112	CcSEcCtD
Ergotamine—Asthenia—Vinblastine—head and neck cancer	0.00506	0.0103	CcSEcCtD
Ergotamine—Myalgia—Fluorouracil—head and neck cancer	0.00483	0.00984	CcSEcCtD
Ergotamine—Hypoaesthesia—Docetaxel—head and neck cancer	0.00468	0.00953	CcSEcCtD
Ergotamine—HTR1D—connective tissue—head and neck cancer	0.00467	0.0151	CbGeAlD
Ergotamine—Asthenia—Hydroxyurea—head and neck cancer	0.00461	0.0094	CcSEcCtD
Ergotamine—Tachycardia—Fluorouracil—head and neck cancer	0.00452	0.0092	CcSEcCtD
Ergotamine—Vomiting—Vinblastine—head and neck cancer	0.00448	0.00913	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00422	0.00859	CcSEcCtD
Ergotamine—Nausea—Vinblastine—head and neck cancer	0.00419	0.00853	CcSEcCtD
Ergotamine—Paraesthesia—Fluorouracil—head and neck cancer	0.00416	0.00847	CcSEcCtD
Ergotamine—Vomiting—Hydroxyurea—head and neck cancer	0.00409	0.00833	CcSEcCtD
Ergotamine—Pain—Fluorouracil—head and neck cancer	0.00396	0.00806	CcSEcCtD
Ergotamine—Nausea—Hydroxyurea—head and neck cancer	0.00382	0.00778	CcSEcCtD
Ergotamine—ADRA1B—head—head and neck cancer	0.00376	0.0122	CbGeAlD
Ergotamine—ADRA1D—head—head and neck cancer	0.00368	0.0119	CbGeAlD
Ergotamine—Hypertension—Docetaxel—head and neck cancer	0.00354	0.0072	CcSEcCtD
Ergotamine—Myalgia—Docetaxel—head and neck cancer	0.00349	0.0071	CcSEcCtD
Ergotamine—ADRA1A—epithelium—head and neck cancer	0.00341	0.011	CbGeAlD
Ergotamine—Pruritus—Fluorouracil—head and neck cancer	0.00328	0.00667	CcSEcCtD
Ergotamine—Tachycardia—Docetaxel—head and neck cancer	0.00326	0.00664	CcSEcCtD
Ergotamine—HTR2A—neck—head and neck cancer	0.00324	0.0105	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00304	0.0062	CcSEcCtD
Ergotamine—Paraesthesia—Docetaxel—head and neck cancer	0.003	0.00611	CcSEcCtD
Ergotamine—Vomiting—Fluorouracil—head and neck cancer	0.00294	0.006	CcSEcCtD
Ergotamine—HTR2B—thyroid gland—head and neck cancer	0.00288	0.00932	CbGeAlD
Ergotamine—Pain—Docetaxel—head and neck cancer	0.00286	0.00582	CcSEcCtD
Ergotamine—HTR1B—head—head and neck cancer	0.00284	0.00918	CbGeAlD
Ergotamine—HTR1D—head—head and neck cancer	0.00275	0.00889	CbGeAlD
Ergotamine—Nausea—Fluorouracil—head and neck cancer	0.00275	0.0056	CcSEcCtD
Ergotamine—ADRA2A—connective tissue—head and neck cancer	0.00273	0.00881	CbGeAlD
Ergotamine—HTR2C—head—head and neck cancer	0.00272	0.0088	CbGeAlD
Ergotamine—ADRA1A—lymphoid tissue—head and neck cancer	0.00262	0.00847	CbGeAlD
Ergotamine—HTR2B—head—head and neck cancer	0.00256	0.00827	CbGeAlD
Ergotamine—Asthenia—Docetaxel—head and neck cancer	0.0024	0.00488	CcSEcCtD
Ergotamine—Pruritus—Docetaxel—head and neck cancer	0.00236	0.00481	CcSEcCtD
Ergotamine—HTR2A—connective tissue—head and neck cancer	0.00232	0.00749	CbGeAlD
Ergotamine—HTR1A—head—head and neck cancer	0.00229	0.00741	CbGeAlD
Ergotamine—ADRA2A—trachea—head and neck cancer	0.00229	0.0074	CbGeAlD
Ergotamine—SLC6A2—head—head and neck cancer	0.00227	0.00735	CbGeAlD
Ergotamine—HTR2A—epithelium—head and neck cancer	0.0022	0.00711	CbGeAlD
Ergotamine—Vomiting—Docetaxel—head and neck cancer	0.00212	0.00433	CcSEcCtD
Ergotamine—ADRA1A—head—head and neck cancer	0.00211	0.00683	CbGeAlD
Ergotamine—DRD2—head—head and neck cancer	0.00207	0.00669	CbGeAlD
Ergotamine—Nausea—Docetaxel—head and neck cancer	0.00198	0.00404	CcSEcCtD
Ergotamine—CYP1A2—thyroid gland—head and neck cancer	0.00197	0.00636	CbGeAlD
Ergotamine—HTR2A—trachea—head and neck cancer	0.00195	0.00629	CbGeAlD
Ergotamine—ADRA2A—thyroid gland—head and neck cancer	0.00181	0.00585	CbGeAlD
Ergotamine—HTR2B—lymph node—head and neck cancer	0.00179	0.00579	CbGeAlD
Ergotamine—ADRA2A—head—head and neck cancer	0.00161	0.00519	CbGeAlD
Ergotamine—SLC6A2—lymph node—head and neck cancer	0.00159	0.00514	CbGeAlD
Ergotamine—ABCB1—epithelium—head and neck cancer	0.00144	0.00466	CbGeAlD
Ergotamine—HTR2A—head—head and neck cancer	0.00137	0.00441	CbGeAlD
Ergotamine—ABCB1—trachea—head and neck cancer	0.00128	0.00412	CbGeAlD
Ergotamine—ADRA2A—lymph node—head and neck cancer	0.00113	0.00364	CbGeAlD
Ergotamine—ABCB1—lymphoid tissue—head and neck cancer	0.00111	0.00359	CbGeAlD
Ergotamine—ABCB1—thyroid gland—head and neck cancer	0.00101	0.00326	CbGeAlD
Ergotamine—ABCB1—head—head and neck cancer	0.000895	0.00289	CbGeAlD
Ergotamine—ABCB1—lymph node—head and neck cancer	0.000627	0.00203	CbGeAlD
Ergotamine—HTR1A—Signaling by GPCR—MAPK1—head and neck cancer	4.9e-05	0.000246	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—EGFR—head and neck cancer	4.9e-05	0.000246	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—YAP1—head and neck cancer	4.89e-05	0.000245	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—PIK3CA—head and neck cancer	4.88e-05	0.000245	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—MAPK1—head and neck cancer	4.88e-05	0.000245	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—EGFR—head and neck cancer	4.88e-05	0.000245	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—HRAS—head and neck cancer	4.88e-05	0.000244	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—HRAS—head and neck cancer	4.85e-05	0.000243	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—PIK3CA—head and neck cancer	4.85e-05	0.000243	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CCND1—head and neck cancer	4.85e-05	0.000243	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NOTCH1—head and neck cancer	4.83e-05	0.000242	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—TP53—head and neck cancer	4.81e-05	0.000241	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—PTEN—head and neck cancer	4.78e-05	0.000239	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—TYMS—head and neck cancer	4.77e-05	0.000239	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—AKT1—head and neck cancer	4.76e-05	0.000239	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	4.76e-05	0.000239	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NOTCH1—head and neck cancer	4.75e-05	0.000238	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—AKT1—head and neck cancer	4.72e-05	0.000237	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—GSTM1—head and neck cancer	4.71e-05	0.000236	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—PIK3CA—head and neck cancer	4.69e-05	0.000235	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—PTEN—head and neck cancer	4.68e-05	0.000234	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—MAPK1—head and neck cancer	4.67e-05	0.000234	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL2—head and neck cancer	4.67e-05	0.000234	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—EGFR—head and neck cancer	4.67e-05	0.000234	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—PIK3CA—head and neck cancer	4.66e-05	0.000234	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—AKT1—head and neck cancer	4.66e-05	0.000234	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NOTCH1—head and neck cancer	4.66e-05	0.000233	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—HRAS—head and neck cancer	4.6e-05	0.000231	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—AKT1—head and neck cancer	4.56e-05	0.000229	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CCND1—head and neck cancer	4.55e-05	0.000228	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—MAPK3—head and neck cancer	4.53e-05	0.000227	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—HRAS—head and neck cancer	4.52e-05	0.000226	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—GPX1—head and neck cancer	4.51e-05	0.000226	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CYP1A1—head and neck cancer	4.47e-05	0.000224	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—PIK3CA—head and neck cancer	4.46e-05	0.000224	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—MAPK3—head and neck cancer	4.45e-05	0.000223	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—PIK3CA—head and neck cancer	4.41e-05	0.000221	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PTEN—head and neck cancer	4.39e-05	0.00022	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—AKT1—head and neck cancer	4.39e-05	0.00022	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—MAPK3—head and neck cancer	4.36e-05	0.000219	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL2—head and neck cancer	4.35e-05	0.000218	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NOTCH1—head and neck cancer	4.33e-05	0.000217	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—VEGFA—head and neck cancer	4.31e-05	0.000216	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—MAPK1—head and neck cancer	4.31e-05	0.000216	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—AKT1—head and neck cancer	4.31e-05	0.000216	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—EGFR—head and neck cancer	4.3e-05	0.000216	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—AKT1—head and neck cancer	4.29e-05	0.000215	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—STAT3—head and neck cancer	4.27e-05	0.000214	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—PIK3CA—head and neck cancer	4.26e-05	0.000213	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—MAPK1—head and neck cancer	4.24e-05	0.000212	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CCND1—head and neck cancer	4.24e-05	0.000212	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—EGFR—head and neck cancer	4.24e-05	0.000212	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—PIK3CA—head and neck cancer	4.23e-05	0.000212	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—VEGFA—head and neck cancer	4.23e-05	0.000212	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—STAT3—head and neck cancer	4.18e-05	0.00021	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	4.15e-05	0.000208	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—MAPK1—head and neck cancer	4.15e-05	0.000208	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—EGFR—head and neck cancer	4.15e-05	0.000208	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—PIK3CA—head and neck cancer	4.11e-05	0.000206	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PTEN—head and neck cancer	4.09e-05	0.000205	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—MAPK3—head and neck cancer	4.08e-05	0.000205	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—HRAS—head and neck cancer	4.08e-05	0.000204	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—AKT1—head and neck cancer	4.06e-05	0.000204	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—PIK3CA—head and neck cancer	4.05e-05	0.000203	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—MAPK3—head and neck cancer	4.05e-05	0.000203	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—PIK3CA—head and neck cancer	4.05e-05	0.000203	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—MAPK3—head and neck cancer	4e-05	0.0002	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—AKT1—head and neck cancer	3.99e-05	0.0002	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—VEGFA—head and neck cancer	3.97e-05	0.000199	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—AKT1—head and neck cancer	3.97e-05	0.000199	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—PIK3CA—head and neck cancer	3.96e-05	0.000199	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—HRAS—head and neck cancer	3.94e-05	0.000197	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—STAT3—head and neck cancer	3.93e-05	0.000197	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL2—head and neck cancer	3.92e-05	0.000197	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	3.92e-05	0.000196	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—MAPK1—head and neck cancer	3.88e-05	0.000195	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—EGFR—head and neck cancer	3.88e-05	0.000195	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—MAPK1—head and neck cancer	3.85e-05	0.000193	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—EGFR—head and neck cancer	3.85e-05	0.000193	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTGS2—head and neck cancer	3.84e-05	0.000193	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—AKT1—head and neck cancer	3.83e-05	0.000192	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CCND1—head and neck cancer	3.82e-05	0.000192	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	3.81e-05	0.000191	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—TYMS—head and neck cancer	3.8e-05	0.000191	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—MAPK1—head and neck cancer	3.8e-05	0.000191	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—EGFR—head and neck cancer	3.8e-05	0.000191	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL2—head and neck cancer	3.79e-05	0.00019	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL2—head and neck cancer	3.77e-05	0.000189	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GSTM1—head and neck cancer	3.76e-05	0.000189	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MAPK3—head and neck cancer	3.75e-05	0.000188	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—HRAS—head and neck cancer	3.75e-05	0.000188	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—PIK3CA—head and neck cancer	3.74e-05	0.000187	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—VEGFA—head and neck cancer	3.69e-05	0.000185	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CCND1—head and neck cancer	3.69e-05	0.000185	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PTEN—head and neck cancer	3.69e-05	0.000185	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—head and neck cancer	3.68e-05	0.000185	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—PIK3CA—head and neck cancer	3.68e-05	0.000184	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CCND1—head and neck cancer	3.67e-05	0.000184	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—STAT3—head and neck cancer	3.66e-05	0.000183	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—AKT1—head and neck cancer	3.65e-05	0.000183	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL2—head and neck cancer	3.61e-05	0.000181	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GPX1—head and neck cancer	3.6e-05	0.000181	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—AKT1—head and neck cancer	3.6e-05	0.000181	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—PIK3CA—head and neck cancer	3.6e-05	0.00018	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MAPK1—head and neck cancer	3.57e-05	0.000179	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EGFR—head and neck cancer	3.57e-05	0.000179	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CYP1A1—head and neck cancer	3.57e-05	0.000179	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PTEN—head and neck cancer	3.56e-05	0.000179	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PTEN—head and neck cancer	3.55e-05	0.000178	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCND1—head and neck cancer	3.52e-05	0.000176	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MAPK3—head and neck cancer	3.49e-05	0.000175	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—AKT1—head and neck cancer	3.48e-05	0.000174	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	3.46e-05	0.000173	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HRAS—head and neck cancer	3.46e-05	0.000173	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	3.4e-05	0.00017	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PTEN—head and neck cancer	3.39e-05	0.00017	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—PIK3CA—head and neck cancer	3.37e-05	0.000169	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—AKT1—head and neck cancer	3.36e-05	0.000168	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTEN—head and neck cancer	3.35e-05	0.000168	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—PIK3CA—head and neck cancer	3.34e-05	0.000168	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—VEGFA—head and neck cancer	3.33e-05	0.000167	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HRAS—head and neck cancer	3.33e-05	0.000167	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL2—head and neck cancer	3.33e-05	0.000167	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MAPK1—head and neck cancer	3.32e-05	0.000167	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EGFR—head and neck cancer	3.32e-05	0.000167	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—AKT1—head and neck cancer	3.31e-05	0.000166	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	3.31e-05	0.000166	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—STAT3—head and neck cancer	3.3e-05	0.000165	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—PIK3CA—head and neck cancer	3.3e-05	0.000165	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL2—head and neck cancer	3.27e-05	0.000164	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—head and neck cancer	3.26e-05	0.000163	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCND1—head and neck cancer	3.24e-05	0.000162	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—AKT1—head and neck cancer	3.24e-05	0.000162	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—VEGFA—head and neck cancer	3.22e-05	0.000161	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL2—head and neck cancer	3.2e-05	0.000161	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	3.2e-05	0.00016	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—head and neck cancer	3.19e-05	0.00016	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCND1—head and neck cancer	3.19e-05	0.00016	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—STAT3—head and neck cancer	3.19e-05	0.00016	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—STAT3—head and neck cancer	3.17e-05	0.000159	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK3—head and neck cancer	3.15e-05	0.000158	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PTEN—head and neck cancer	3.13e-05	0.000157	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCND1—head and neck cancer	3.12e-05	0.000157	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HRAS—head and neck cancer	3.12e-05	0.000156	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PIK3CA—head and neck cancer	3.1e-05	0.000155	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HRAS—head and neck cancer	3.09e-05	0.000155	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PTEN—head and neck cancer	3.08e-05	0.000154	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—VEGFA—head and neck cancer	3.07e-05	0.000154	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HRAS—head and neck cancer	3.05e-05	0.000153	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—AKT1—head and neck cancer	3.05e-05	0.000153	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK3—head and neck cancer	3.04e-05	0.000153	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—STAT3—head and neck cancer	3.03e-05	0.000152	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	3.03e-05	0.000152	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PTEN—head and neck cancer	3.01e-05	0.000151	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—AKT1—head and neck cancer	3.01e-05	0.000151	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	3e-05	0.000151	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK1—head and neck cancer	3e-05	0.00015	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EGFR—head and neck cancer	3e-05	0.00015	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—head and neck cancer	3e-05	0.00015	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL2—head and neck cancer	2.98e-05	0.000149	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—AKT1—head and neck cancer	2.94e-05	0.000147	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TYMS—head and neck cancer	2.94e-05	0.000147	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.93e-05	0.000147	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTM1—head and neck cancer	2.9e-05	0.000145	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCND1—head and neck cancer	2.9e-05	0.000145	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK3—head and neck cancer	2.9e-05	0.000145	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK1—head and neck cancer	2.9e-05	0.000145	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EGFR—head and neck cancer	2.9e-05	0.000145	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PIK3CA—head and neck cancer	2.88e-05	0.000145	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	2.88e-05	0.000144	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EGFR—head and neck cancer	2.88e-05	0.000144	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HRAS—head and neck cancer	2.87e-05	0.000144	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—VEGFA—head and neck cancer	2.83e-05	0.000142	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PTEN—head and neck cancer	2.8e-05	0.00014	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—STAT3—head and neck cancer	2.8e-05	0.00014	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—head and neck cancer	2.79e-05	0.00014	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	2.78e-05	0.000139	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GPX1—head and neck cancer	2.78e-05	0.000139	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK1—head and neck cancer	2.76e-05	0.000138	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EGFR—head and neck cancer	2.76e-05	0.000138	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—STAT3—head and neck cancer	2.75e-05	0.000138	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—AKT1—head and neck cancer	2.75e-05	0.000138	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP1A1—head and neck cancer	2.75e-05	0.000138	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—AKT1—head and neck cancer	2.73e-05	0.000137	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—VEGFA—head and neck cancer	2.72e-05	0.000136	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—AKT1—head and neck cancer	2.7e-05	0.000135	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—STAT3—head and neck cancer	2.7e-05	0.000135	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK3—head and neck cancer	2.67e-05	0.000134	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HRAS—head and neck cancer	2.67e-05	0.000134	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—head and neck cancer	2.66e-05	0.000133	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	2.63e-05	0.000132	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PIK3CA—head and neck cancer	2.6e-05	0.000131	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK3—head and neck cancer	2.58e-05	0.000129	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK1—head and neck cancer	2.54e-05	0.000127	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EGFR—head and neck cancer	2.54e-05	0.000127	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—AKT1—head and neck cancer	2.53e-05	0.000127	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—VEGFA—head and neck cancer	2.53e-05	0.000127	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—head and neck cancer	2.52e-05	0.000126	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PIK3CA—head and neck cancer	2.51e-05	0.000126	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—STAT3—head and neck cancer	2.5e-05	0.000126	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	2.5e-05	0.000125	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EGFR—head and neck cancer	2.5e-05	0.000125	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	2.5e-05	0.000125	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK1—head and neck cancer	2.45e-05	0.000123	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EGFR—head and neck cancer	2.45e-05	0.000123	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—head and neck cancer	2.43e-05	0.000122	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—head and neck cancer	2.42e-05	0.000121	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HRAS—head and neck cancer	2.41e-05	0.000121	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PIK3CA—head and neck cancer	2.39e-05	0.00012	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK3—head and neck cancer	2.39e-05	0.00012	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PIK3CA—head and neck cancer	2.36e-05	0.000118	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—AKT1—head and neck cancer	2.36e-05	0.000118	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HRAS—head and neck cancer	2.33e-05	0.000117	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTEN—head and neck cancer	2.32e-05	0.000116	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—head and neck cancer	2.32e-05	0.000116	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HRAS—head and neck cancer	2.31e-05	0.000116	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK1—head and neck cancer	2.28e-05	0.000114	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EGFR—head and neck cancer	2.28e-05	0.000114	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HRAS—head and neck cancer	2.21e-05	0.000111	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PIK3CA—head and neck cancer	2.21e-05	0.000111	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	2.17e-05	0.000109	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—head and neck cancer	2.14e-05	0.000107	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—AKT1—head and neck cancer	2.13e-05	0.000107	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CA—head and neck cancer	2.13e-05	0.000107	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—head and neck cancer	2.12e-05	0.000106	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—head and neck cancer	2.1e-05	0.000105	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—head and neck cancer	2.06e-05	0.000103	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—AKT1—head and neck cancer	2.05e-05	0.000103	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—AKT1—head and neck cancer	2.04e-05	0.000102	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HRAS—head and neck cancer	2.04e-05	0.000102	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HRAS—head and neck cancer	2.01e-05	0.000101	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CA—head and neck cancer	1.98e-05	9.9e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HRAS—head and neck cancer	1.97e-05	9.86e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—AKT1—head and neck cancer	1.96e-05	9.8e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—AKT1—head and neck cancer	1.93e-05	9.68e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—head and neck cancer	1.91e-05	9.58e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTEN—head and neck cancer	1.85e-05	9.27e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HRAS—head and neck cancer	1.83e-05	9.16e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—AKT1—head and neck cancer	1.8e-05	9.04e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—AKT1—head and neck cancer	1.77e-05	8.89e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—AKT1—head and neck cancer	1.74e-05	8.71e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.64e-05	8.2e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CA—head and neck cancer	1.63e-05	8.19e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—AKT1—head and neck cancer	1.61e-05	8.09e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTEN—head and neck cancer	1.43e-05	7.15e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—AKT1—head and neck cancer	1.33e-05	6.69e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CA—head and neck cancer	1.3e-05	6.54e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AKT1—head and neck cancer	1.07e-05	5.34e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.01e-05	5.05e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AKT1—head and neck cancer	8.22e-06	4.12e-05	CbGpPWpGaD
